pneumonia%20-%20hospital-acquired
PNEUMONIA - HOSPITAL-ACQUIRED
Hospital-acquired pneumonia (HAP) is defined as pneumonia occurring ≥48 hours after admission and excluding any infection that is incubating at the time of admission.
Ventilator-associated pneumonia (VAP) is described as pneumonia occurring >48-72 hours after endotracheal intubation and within 48 hours after removal of endotracheal tube.
Early-onset HAP or VAP is the pneumonia occurring within the first 4 days of hospitalization that may be cause by antibiotic-sensitive bacteria that usually carries a better diagnosis.
Late-onset HAP or VAP is the pneumonia occurring after ≥5 days. It is likely caused by multidrug-resistant pathogens associated with increased mortality and morbidity.

Diagnosis

  • The clinical approach to define pneumonia makes use of clinical evidence & radiographic findings
  • Clinical Pulmonary Infection Score (CPIS) is used to quantify clinical, radiographic, microbiologic & physiological findings
    • A threshold score of >6 leads to a diagnosis of hospital-acquired pneumonia (HAP); has a sensitivity of 77% & specificity value of 42%
    • May be useful in selecting patients for short-course antibiotic therapy & monitoring of response to treatment

Assessment

CURB65 Scoring System for Mortality Risk Assessment
  • May be used as a prognostic baseline for patients diagnosed w/ hospital-acquired pneumonia
Prognostic Features (1 point for each feature present)
  • Confusion (abbreviated Mental Test score ≤8 or new disorientation)
  • Increased blood urea nitrogen (≥7 mmol/L)
  • Increased respiratory rate (≥30 breaths/min)
  • Decreased blood pressure (≤90/60 mmHg)
  • ≥65 years old
Stratification:
  • 0 or 1: Low risk (<3% mortality risk)
  • 2: Moderate risk (3-15% mortality risk)
  • 3-5: High risk (>15% mortality risk)

History

  • Thorough history & physical exam are performed to define the severity of the pneumonia
  • They can elicit presence of specific conditions that can have an impact on the likely pathogens
  • Exclude other potential sources of infection

Laboratory Tests

Cultures
  • Should be collected before antibiotics are started or changed
  • Blood
    • Two sets from separate sites
    • If blood cultures (BC) isolate a pathogen, other sites of infection will need to be excluded
  • Sputum, pleural fluid
  • Endotracheal or transtracheal aspirate
Invasive Microbiologic Techniques
  • Usually confined to intubated patients
  • Invasive procedures [eg bronchoscopy w/ protected specimen brushing (PSB) &/or bronchoalveolar lavage (BAL)]
  • Etiologic pathogen is determined if a specimen contains organism(s) above a predetermined threshold concentration
Arterial Blood Gas or Oximetry
  • Generally measured in all patients to determine the severity of illness & the need for supplemental O2 or mechanical ventilation
Other Laboratory Tests
  • Complete blood count (CBC), serum electrolytes, renal & liver function
  • A baseline C-reactive protein may be obtained for assessment of response to therapy 48-72 hours after admission
  • Not useful for determining the etiologic organism
  • May be useful to document presence of organ dysfunction to assist in determining the severity of illness

Imaging

Chest X-ray (CXR)
  • Both posterior-anterior (PA) & lateral views are recommended
  • Helps to identify disease severity & presence of complications (eg effusion, cavitation)

Clinical evidence that new or progressive infiltrate is consistent of pneumonia

  • At least 2 of the following should be present:
    • Fever >38°C
    • Purulent sputum
    • Leukocytosis [WBC >12,000 cells/mm3 (12x109 cells/L)] or leukopenia [WBC <4,000 cells/mm3 (4x109 cells/L)]
  • There is high sensitivity even if only 1 criterion is used, but low specificity is noted for ventilator-associated pneumonia (VAP)
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 19 Jan 2018

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

20 Feb 2018
Dr Michael Lim, consultant of the Division of Paediatric Pulmonary and Sleep in National University Hospital, Singapore, shares his insights with Pearl Toh on diagnosing and managing paediatric asthma in the primary care setting.